Literature DB >> 22553342

Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.

Elena Tassi1, Marina Zanon, Claudia Vegetti, Alessandra Molla, Ilaria Bersani, Valentina Perotti, Marzia Pennati, Nadia Zaffaroni, Michele Milella, Soldano Ferrone, Carmelo Carlo-Stella, Alessandro M Gianni, Roberta Mortarini, Andrea Anichini.   

Abstract

PURPOSE: To assess the role of Apollon in melanoma resistance to intrinsic and extrinsic pathways of apoptosis and to identify strategies to reduce its expression. EXPERIMENTAL
DESIGN: Apollon expression was assessed in melanoma cells in vitro and in vivo. Apollon modulation and melanoma apoptosis were evaluated by Western blot and/or flow cytometry in response to cytotoxic drugs, mitogen-activated protein/extracellular signal-regulated kinase (MEK)-, BRAF(V600E)-, and mTOR-specific inhibitors, TRAIL and anti-HLA class II monoclonal antibodies (mAb). Mitochondrial depolarization, caspase activation, apoptosis assays, and gene expression profiling were used to test effects of Apollon silencing, by siRNA, on melanoma response to antitumor agents.
RESULTS: Apollon was constitutively expressed by melanoma cells, in vitro and in vivo, and at higher levels than in benign melanocytic lesions. Melanoma apoptosis correlated significantly with Apollon protein downmodulation in response to cytotoxic drugs, MEK, or BRAF(V600E)-specific inhibitors. Combinatorial treatment with MEK and mTOR inhibitors and HLA class II ligation, by a specific mAb, promoted Apollon downmodulation and enhanced melanoma apoptosis. Apollon downmodulation induced by antitumor agents was caspase independent, but proteasome dependent. Knockdown of Apollon, by siRNA, triggered apoptosis and/or significantly enhanced melanoma cell death in response to cytotoxic drugs, MEK- and BRAF(V600E)-specific inhibitors, and soluble or membrane-bound TRAIL. Apollon silencing promoted mitochondrial depolarization and caspase-2, caspase-8, caspase-9, and caspase-3 activation in response to different antitumor agents and altered the profile of genes modulated by MEK or BRAF(V600E)-specific inhibitors.
CONCLUSIONS: Targeting of Apollon may significantly improve melanoma cell death in response to antitumor agents that trigger the intrinsic or the extrinsic apoptosis pathways. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22553342      PMCID: PMC3426233          DOI: 10.1158/1078-0432.CCR-11-2232

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.

Authors:  V Jaks; A Jõers; A Kristjuhan; T Maimets
Journal:  Oncogene       Date:  2001-03-08       Impact factor: 9.867

2.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma.

Authors:  D Grossman; J M McNiff; F Li; D C Altieri
Journal:  J Invest Dermatol       Date:  1999-12       Impact factor: 8.551

3.  Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification.

Authors:  M Temponi; T Kageshita; F Perosa; R Ono; H Okada; S Ferrone
Journal:  Hybridoma       Date:  1989-02

4.  Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents.

Authors:  Marina Zanon; Adriano Piris; Ilaria Bersani; Claudia Vegetti; Alessandra Molla; Alessia Scarito; Andrea Anichini
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

5.  Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.

Authors:  Zoltan A Nagy; Bernd Hubner; Corinna Löhning; Robert Rauchenberger; Silke Reiffert; Elisabeth Thomassen-Wolf; Stefan Zahn; Sigmar Leyer; Eva M Schier; Angelika Zahradnik; Christoph Brunner; Kurt Lobenwein; Benno Rattel; Michael Stanglmaier; Michael Hallek; Mark Wing; Steve Anderson; Matt Dunn; Titus Kretzschmar; Michael Tesar
Journal:  Nat Med       Date:  2002-07-08       Impact factor: 53.440

6.  Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.

Authors:  M Chawla-Sarkar; S I Bae; F J Reu; B S Jacobs; D J Lindner; E C Borden
Journal:  Cell Death Differ       Date:  2004-08       Impact factor: 15.828

7.  BRAF alterations are associated with complex mutational profiles in malignant melanoma.

Authors:  Maria Daniotti; Maria Oggionni; Tiziana Ranzani; Viviana Vallacchi; Valentina Campi; Delia Di Stasi; Gabriella Della Torre; Federica Perrone; Chiara Luoni; Simona Suardi; Milo Frattini; Silvana Pilotti; Andrea Anichini; Gabrina Tragni; Giorgio Parmiani; Marco A Pierotti; Monica Rodolfo
Journal:  Oncogene       Date:  2004-08-05       Impact factor: 9.867

8.  Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis.

Authors:  Xiao-Bo Qiu; Shirley L Markant; Junying Yuan; Alfred L Goldberg
Journal:  EMBO J       Date:  2004-02-12       Impact factor: 11.598

9.  Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function.

Authors:  Yanyan Hao; Keiko Sekine; Atsushi Kawabata; Hitoshi Nakamura; Toshiyasu Ishioka; Hirokazu Ohata; Ryohei Katayama; Chizuko Hashimoto; Xiaodong Zhang; Tetsuo Noda; Takashi Tsuruo; Mikihiko Naito
Journal:  Nat Cell Biol       Date:  2004-08-08       Impact factor: 28.824

10.  Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.

Authors:  C C Jiang; F Lai; K H Tay; A Croft; H Rizos; T M Becker; F Yang; H Liu; R F Thorne; P Hersey; X D Zhang
Journal:  Cell Death Dis       Date:  2010-09-02       Impact factor: 8.469

View more
  14 in total

1.  NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Authors:  V Perotti; P Baldassari; A Molla; C Vegetti; I Bersani; A Maurichi; M Santinami; A Anichini; R Mortarini
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

2.  Knockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic Agents.

Authors:  Jason B Garrison; Chunmin Ge; Lixiao Che; Derek A Pullum; Guang Peng; Sohaib Khan; Nira Ben-Jonathan; Jiang Wang; Chunying Du
Journal:  J Cancer Sci Ther       Date:  2015-04

3.  Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

Authors:  G Grazia; C Vegetti; F Benigni; I Penna; V Perotti; E Tassi; I Bersani; G Nicolini; S Canevari; C Carlo-Stella; A M Gianni; R Mortarini; A Anichini
Journal:  Cell Death Dis       Date:  2014-10-02       Impact factor: 8.469

4.  Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.

Authors:  Rossella Loria; Giulia Bon; Valentina Perotti; Enzo Gallo; Ilaria Bersani; Paola Baldassari; Manuela Porru; Carlo Leonetti; Selene Di Carlo; Paolo Visca; Maria Felice Brizzi; Andrea Anichini; Roberta Mortarini; Rita Falcioni
Journal:  Oncotarget       Date:  2015-02-20

Review 5.  Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).

Authors:  Giulia Grazia; Ilaria Penna; Valentina Perotti; Andrea Anichini; Elena Tassi
Journal:  Int J Oncol       Date:  2014-06-10       Impact factor: 5.650

6.  Exploration of potential roles of a new LOXL2 splicing variant using network knowledge in esophageal squamous cell carcinoma.

Authors:  Bing-Li Wu; Guo-Qing Lv; Hai-Ying Zou; Ze-Peng Du; Jian-Yi Wu; Pi-Xian Zhang; Li-Yan Xu; En-Min Li
Journal:  ScientificWorldJournal       Date:  2014-08-31

7.  Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

Authors:  Ilaria Penna; Alessandra Molla; Giulia Grazia; Loredana Cleris; Gabriella Nicolini; Federica Perrone; Benedetta Picciani; Michele Del Vecchio; Filippo de Braud; Roberta Mortarini; Andrea Anichini
Journal:  Oncotarget       Date:  2016-01-26

8.  Expression and clinical significance of Apollon in esophageal squamous cell carcinoma.

Authors:  Rong Li; Bo-Lin Chen; Yan-Wu Zhou; Ren-Wei Guo; Meng-Ting Shuai; Jun-Xian Zeng; Ai-Min Leng
Journal:  Mol Med Rep       Date:  2016-07-06       Impact factor: 2.952

9.  Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles.

Authors:  Cristina Tringali; Ilaria Silvestri; Francesca Testa; Paola Baldassari; Luigi Anastasia; Roberta Mortarini; Andrea Anichini; Alejandro López-Requena; Guido Tettamanti; Bruno Venerando
Journal:  BMC Cancer       Date:  2014-08-01       Impact factor: 4.430

10.  The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.

Authors:  Sze Ue Iris Luk; Hui Xue; Hongwei Cheng; Dong Lin; Peter W Gout; Ladan Fazli; Colin C Collins; Martin E Gleave; Yuzhuo Wang
Journal:  Oncotarget       Date:  2014-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.